Polatuzumab vedotin-piiq (POLIVY) + bendamustine + rituximab (BR) is included as a preferred treatment option (Category 2A) based on the randomized, controlled GO29365 trial 1,2*

The National Comprehensive Cancer Network® (NCCN®) makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed January 27, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org.
*See NCCN Guidelines® in Oncology (NCCN Guidelines®) for a complete list of regimens.

NCCN Categories of Evidence and Consensus 2

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations in the NCCN Guidelines are considered appropriate.
Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2020. © 2020 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

Access the NCCN Guidelines for B-Cell Lymphomas